Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

If the STAR-2 study yields positive results, the Phase 3 program will support the filing of a new drug application with the U.S. Food and Drug Administration. Dermata’s announcement underscores the ...

Xyngari met all three primary endpoints in the STAR-1 Phase 3 trial, showing a statistically significant improvement in acne severity. Dermata plans to start the STAR-2 Phase 3 trial for Xyngari ...